Archer Materials (ASX:AXE) partnered with Canadian medical device company Hylid Diagnostics to develop a potassium measurement product for testing chronic kidney disease in its Biochip project, according to a Monday filing with the Australian bourse.
The partnership will use the company's potassium sensing technology and Hylid Diagnostics' blood hemolysis sensor technology to develop a prototype cartridge system, the filing said.
The companies are developing a detailed work plan for the next few months, according to the filing.
Archer Materials shares fell 5% in midday trade Tuesday.